PMV Pharmaceuticals
PMVP
81 hedge funds and large institutions have $1.31B invested in PMV Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
11% more funds holding
Funds holding: 73 → 81 (+8)
3.78% more ownership
Funds ownership: 85.36% → 89.14% (+3.8%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
44% less capital invested
Capital invested by funds: $2.34B → $1.31B (-$1.02B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$35.4M |
| 2 |
PCS
Personal CFO Solutions
Chester,
New Jersey
|
+$33.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.9M |
| 4 |
DM
Deerfield Management
New York
|
+$9.32M |
| 5 |
Jennison Associates
New York
|
+$8.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$39.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.7M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$10.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.48M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$2.59M |
PMVP Hedge Fund Activity: Q1 2021 in Review
81 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2021, worth a combined $1.31B — down 44% from $2.34B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PMVP positions and 7 closed out — a net gain of 8 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $35.4M. The largest seller was InterWest Venture Management, cutting an estimated $39.4M.
- 81 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2021, up from 73 in Q4 2020.
- Funds reported $1.31B of PMV Pharmaceuticals stock for Q1 2021, down 44% quarter-over-quarter.
- 15 funds opened new PMV Pharmaceuticals positions in Q1 2021 and 7 closed out, a net change of +8 holders.
- The largest PMV Pharmaceuticals buyer in Q1 2021 was JP Morgan Chase, an estimated $35.4M added.
- The largest PMV Pharmaceuticals seller in Q1 2021 was InterWest Venture Management, an estimated $39.4M sold.
Based on aggregated 13F filings for Q1 2021.